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Abstract
Background: Breast cancer is the commonest female malignancy globally and the second (after uterine cervix) in
sub-Saharan Africa including Tanzania. Prognostic indicators reportedly influence post-mastectomy adjuvant therapy
by predicting risks on survival and recurrence although in Tanzania this data is lacking. Here, we evaluate the
pattern of prognostic and risk indicators among women with breast cancer undergoing modified-radical-
mastectomy (MRM) at Muhimbili National Hospital (MNH) and Tumaini Hospital (TH), Dar es Salaam, Tanzania.
Methods: This hospital-based prospective cross-sectional study included female patients undergoing MRM from
April 2011 to January 2012. Clinical stage I-III patients were enrolled after being scheduled for mastectomy. Patients
with evidence of distant metastasis (stage IV) were excluded. Mastectomy and axillary lymph nodes biopsies were
submitted to the Histopathology laboratory for grade, type, nodal and margins status. Data was collected using a
structured questionnaire and analyzed using SPSS.
Results: A total of 348 patients were admitted with breast cancer including 86 patients (with 16 from TH having
similar demography and presentation) meeting inclusion criteria. Age-range at diagnosis was 28–79 years, mean
52.1 years. Most (89 %) attained menarche after 11 years. About 56 % were postmenopausal. The majority (78 %)
were multiparous with positive family history in 14.1 and 37.6 % used hormonal contraceptives.
About 27.1 % were social alcohol drinkers. The majority (61 %) had T4b disease, 75.6 % had positive axillary nodes
including 42.7 % with 4–9 involved nodes (N2). The commonest (91.9 %) histological type was invasive ductal
carcinoma. Lobular, medullary and mucinous carcinomas were rare. Most (83.7 %) of our patients presented with
stage III and the rest stage II. Intermediate- and high-grade tumors accounted for 73.5 %. Following MRM, 25 % of
our patients had positive surgical margins and similarly for the base.
Conclusions: Most of our breast cancer patients present with frequent risks including younger age, multiparity,
hormonal contraceptives use, alcohol use and family history. Unfavourable prognostic indicators including late
stages, large primary tumor size, skin infiltration, positive surgical margins, positive axillary lymph nodes and a high
histological grade were associated.
A sustainable screening program by self-examination to allow early diagnosis is needed to reduce morbidity and
mortality from this cancer.
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Background
Breast cancer is the most frequently diagnosed cancer
globally and the leading cause of cancer death among fe-
males, accounting for 23 % of the total cancer cases and
14 % of the cancer deaths [1]. Breast cancer is the sec-
ond most common malignancy among females in sub-
Saharan African countries including Tanzania, the lead-
ing cancer being of that of the uterine cervix [2]. In
Tanzania, the Ocean Road Cancer Institute (ORCI) is
the main centre of care for cancer patients. Its 2004
registry reported admission of 10–20 patients with
breast cancer per month [2].
The prognosis of patients with breast cancer is influ-
enced by a number of factors including those which are
tumor-related including the size of the primary carcin-
oma, lymph node involvement and the number of lymph
nodes involved by metastases. Studies have shown that
the presence of estrogen and progesterone receptors and
currently HER2 to influence the prognosis of patients
with breast cancer [3]. The presence of estrogen and
progesterone receptors is important clinically as a pre-
dictor for response to adjuvant hormonal therapy rather
than prognostic factors [4]. The presence of hormone
receptors (ER and PR) in the tumor tissue correlates well
with the response to hormonal therapy and chemother-
apy [5]. HER2 over expression in patients with breast
cancer has been associated with poor prognosis and re-
sistance to treatment [6]. The histological type of the
tumor is one of the important prognostic indicators in
breast cancer as it influences the form of treatment.
Ductal carcinoma in situ (DCIS) is a pre-invasive breast
cancer that can almost always be cured by local-regional
therapy. The most common histological grading system
for breast cancer evaluates tubule formation, nuclear
grade, and mitotic rate to divide carcinomas into well-
differentiated carcinomas which have a significantly bet-
ter prognosis as compared with poorly differentiated car-
cinomas. Moderately differentiated carcinomas initially
have a better prognosis, but survival at 20 years ap-
proaches that of poorly differentiated carcinomas [7].
The clinical stage of breast cancer is among the factors
influencing the prognosis of these patients. Late presen-
tation to hospital is still a challenging factor in Tanzania
where only 5.2 % patients present with Stage II disease,
57 % stage III and 37.5 % stage IV. Stage I disease pa-
tients are rarely found [8]. Studies have shown that only
5 to 12 % of Stage I/II patients die in the first 10 years
after diagnosis, compared with over 60 % of Stage III pa-
tients and over 90 % of Stage IV patients. Breast cancer
staging also provides valuable information about appro-
priate treatment options for each cancer stage [9]. Post-
mastectomy radiotherapy is always recommended for
patients with stage IIB disease who have four or more
positive axillary nodes. Other risk factors are patient-
related including age, reproductive career, and meno-
pausal status, family history, alcohol use, tobacco smok-
ing and use of hormornal contraceptives. It has been
found that younger patients in general, have favourable
prognosis as compared to older women [10, 11]. How-
ever, age under 30 years has been postulated to have a
worse prognosis [12, 13].
The natural history of breast cancer influences its
management in which both local and systemic control of
the disease, are of great importance. Depending on the
stage of the disease, management of breast cancer can
be individualized [14]. This would in part depend on
predisposing risks as well as prognostic factors and thus
these need to be elucidated in our settings in order to
inform treatment and prevention/control strategies.
The current practice of treatment of breast cancer pa-
tients at our institution depending on the stage of the
disease includes neoadjuvant therapy followed by mast-
ectomy or mastectomy with adjuvant therapy. Patients
destined for recurrence can be selected for systemic ad-
juvant therapy, and patients who will not have a recur-
rence can be spared the morbidity of a treatment that
offers no benefit [15]. Knowledge of the prognostic indi-
cators of patients with breast cancer before and after
surgical intervention may assist in proper management
of these patients including the determination as to who
will benefit from specific adjuvant therapy.
In Tanzania, studies on prognostic indicators of pa-
tients with breast cancer including late presentation,
histological grade, axillary lymph node status, surgical
margins and base status, presence of bilateral disease,
hormone receptor status and HER2 status and others,
are not yet well documented. Thus, the current study
aims at enlightening surgeons, oncologists as well as pa-
thologists and other stakeholders who care for breast
cancer patients by elucidating the pattern of disease
presentation within our settings so as to allow the for-
mulation of improved as well as individualized manage-
ment resulting in increased survival and quality of life.
This is particularly important in a country like Tanzania
where post-treatment follow-up of patients is greatly
limited by logistical constraints on the part of both the
patient and cancer care providers.
Methods
Study design
Hospital-based prospective descriptive study.
Study area
The study was conducted in the female surgical wards and
the Histopathology Unit of the Department of Laboratory
Services at MNH as well as the female surgical wards at
Tumaini Hospital (TH) in Dar es Salaam, Tanzania from
April 2011 to January 2012. The two hospitals were chosen
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due to geographical proximity and to allow the use of a
comparable standard type of mastectomy during the study
since both hospitals use Auchincloss type. Furthermore,
most surgeons operating at MNH also work at Tumaini
Hospital. It is also noteworthy that most patients going to
TH came from MNH but resorted to the former due to
long waiting lists. Importantly also, TH accepts patients
with National Health Insurance Fund (NHIF) cards, just
like MNH thus they are not necessarily of different socio-
economic status.
Treatment modalities
The current practice of treatment of breast cancer pa-
tients at MNH depends on the stage of the disease and
includes neoadjuvant therapy followed by mastectomy
or mastectomy with adjuvant therapy. Patients destined
for recurrence can be selected for systemic adjuvant
therapy, and patients who will not have a recurrence can
be spared the morbidity of a treatment that offers no
benefit. Such decisions are conducted at a Multidiscip-
linary Tumour Board at MNH every Tuesday at 2.00 pm
and attended by specialists from both MNH and ORCI.
It consists of Surgeons, Gynaecologists, Oncologists as
well as Pathologists who form the Secretariat while Oncol-
ogists chair the Board. Breast cancer patients are therefore
generally categorized as premenopausal and postmeno-
pausal. Premenopausal would be treated with chemother-
apy, surgery and radiotherapy depending on staging while
postmenopausal women will be treated with hormonal
therapy (Tamoxifen), surgery and radiotherapy depending
on staging as well. We do not give hormonal therapy to all
breast cancer patients currently but we base on the meno-
pausal status as well as ER/PR status where the later can
be/has been done. Up to now there is no routine receptor
status testing in Tanzania due to cost.
Study population and sampling
All women admitted in general surgical wards with clin-
ical stage I to III breast cancer as classified by TNM sta-
ging system undergoing MRM from April 2011 to
January 2012 were included in the study.
Inclusion criteria
All patients admitted in female surgical wards with clin-
ical stage I to III breast cancer who underwent MRM
from April 2011 to January 2012 were included in the
study.
Exclusion criteria
Patients with recurrent breast cancer, those who under-
went neoadjuvant therapy, Stage I-III disease without axil-
lary dissection as well as patients with stage IV disease
were excluded from the study. The patients with recurrent
breast cancer and those who underwent neoadjuvant
therapy were excluded since the therapy alters the primary
lesion, stage III patients may be down staged to stage II.
Since clinical stage was one of the prognostic indicators
studied, down-staged patients were excluded to avoid get-
ting the wrong impression of clinical stage of studied pa-
tients at presentation to hospital. Patients who did not
have axillary node dissection (both stage I-III and IV)
were excluded since node status was also one of the prog-
nostic indicators studied.
Limitations of the study
This study did not cover hormonal receptors as well as
HER2 determination because this was also a time bound
and very financially limited student research exercise.
The money available could not support at all hormone
studies. This is not only a problem for this work but for
most if not all of our public funded student research ac-
tivities. Furthermore, immunohistochemistry including
for hormone receptors is expensive globally and is not
yet routine in Tanzania. Patients are therefore generally
categorized as premenopausal and postmenopausal ex-
cept in situtations where hormonal receptors have been
done. Premenopausal would generally be treated with
chemotherapy, surgery and radiotherapy depending on
staging while postmenopausal women will be treated
with hormonal therapy (tamoxifen), surgery and radio-
therapy depending on staging as well.
Data sources
Histopathology reports following FNAC or incision
biopsy were used to confirm diagnosis of breast car-
cinoma while chest X-rays and abdominal pelvic ul-
trasounds reports to exclude stage IV patients.
Physical examination was done by HR to obtain clin-
ical stage, assess for clinically bilateral disease and
signs of metastasis (pleural effusion or ascites). Histo-
pathology reports as well as slides following mastec-
tomy and axillary dissection were reviewed by ARM
and HR and relevant information collected.
Biopsies
The whole breast and lymph nodes were submitted to
the histopathology unit and formalin-fixed and paraffin
embedded (FFPE) tissue blocks were prepared as previ-
ously described [16, 17]. Glass slides were stained with
hematoxylin-eosin. The sections were reviewed to deter-
mine the histopathological type, grade, node positivity,
status of surgical margins and the base. Nuclear pleo-
morphism, tumor differentiation (well differentiated,
moderate and poorly differentiated) as well as mitotic
figure counts per one high power field were used to
grade the tumor, where mitotic figure counts of 1–2 was
regarded as low grade, 3–5 intermediate grade and
above 5 high grade.
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Histopathology
Primary histological diagnosis on hematoxylin and eosin
(H & E) stained formalin-fixed paraffin embedded
(FFPE) sections was done as previously described at
MNH [17, 18].
Data collection
Data was collected by HR who was a Surgery Resident at
the time and two research assistants; one in the ward
and another in the laboratory who took mastectomy
specimens to the Histopathologist (ARM) and also col-
lected slides in order to review the histological grades
which were seldom reported on routine histopathology
results. Questionnaires were filled by HR and the assist-
ant in the ward to obtain demographic data,
gynecological history and details of clinical findings of
the patient like tumor size, regional node involvement,
bilaterality of the disease as well as histopathological in-
formation including the type of tumor, grade, number of
lymphnodes submitted, number of lymphnodes positive
for tumor, surgical margins and base status.
Data handling and analysis
Data was entered in structured questionnaires which
were given serial numbers in addition to hospital file
numbers to assist in keeping record in a systematic man-
ner. The copy of histopathology report of every patient
was attached to the respective questionnaire. All histo-
pathology reports with inadequate information were
identified and slide number recorded for review. Patient
details and results were entered into statistical
programme for social scientists (SPSS) version 17 (IBM,
USA) and data and analysis was done. Fisher’s exact and
t-test was used in analysis and attaining statistical signifi-
cance. P-value of <0.05 was considered significant.
Ethical consideration
In this study, ethical clearance was sought and obtained
from the MUHAS Ethical Committee and permission to
conduct the study was sought from relevant authorities
at MNH. The study did not change the form of treat-
ment planned for the patients. No individual participant
data is reported in the manuscript and patient informa-
tion was handled in a strictly confidential way. No per-
sonal identifiers were used. Informed consent with detail
on the purpose of the study, the rights of the participant




Between the month of April 2011 and January 2012, a
total of 348 patients were admitted with breast cancer
including 86 patients (out of this 16 came from Tumaini
Hospital) with breast carcinoma stage I-III who under-
went modified radical mastectomy (MRM) and thus met
the inclusion criteria. The age range was 28–79 years;
with mean age at diagnosis of 52.08 years. The peak age-
group was 36–55 years and accounted for 54.6 % of pa-
tients studied. The majority were indigenous Africans
with only about 1.2 % Caucasians. This was expected be-
cause in Tanzania, indigenous Africans are the majority.
Among the study population, 5.8 % were smokers and
26.7 % were social alcohol drinkers. The demography
and clinical presentation of patients from TH were com-
parable to those of MNH.
Eighty nine (89 %) of study population attained menarche
after the age of 11 years, with mean age at 14.4 years. Fifty
seven (57 %) were postmenopausal with 24.5 % attaining
menopause at the age of 55 years or more. About 79 %
were multiparous, with only 7 % nulliparous.
Most (87.5 %) of them had their first live birth before
the age of 30 years. Family history of breast cancer was
reported in 14 % of patients and 37.2 % reported use of
hormonal contraceptives.
Prognostic indicators and histopathology
A great majority (83.7 %, n = 72/86) were in clinical stage
III and the majority (42.7 %, n = 35/86) of patients also
had high (4–9) number of positive lymph nodes. Fur-
thermore, most (73.5 %, n = 61/86) patients had high or
intermediate histological grades as compared to those
with low grade [Table 1, Fig. 1 (a-f )]. Those tumors with
high grade included those with pleomorphic histology
[Fig. 2 (a & b)]. The majority (60.5 %, n = 52/86) of
women in our study had T4 tumors and none-had T1
(Table 1). T4 tumors included those with large size of
primary tumor as well as those with skin involvement
including ulceration [Fig. 2 (c-f )]. The findings of our
current study imply that our patients mostly present
with advanced disease (Table 1). Infiltrating ductal car-
cinoma was the most common (91.9 %, n = 79/86) histo-
logical type of tumor seen, while infiltrating lobular
carcinoma accounted for 2.3 %. And medullary breast
carcinoma was seen in 1.2 % [Table 1, Fig. 1 (a-f )]. Other
histological types included both infiltrating ductal and
lobular occurring in conjunction, metaplastic carcinoma,
mucinous carcinoma and apocrine carcinoma constitut-
ing 4.7 %.
Following modified radical mastectomy, 25 % of the pa-
tients had tumor positive side surgical margins and 75 %
had margins free from tumor (Table 2, Fig. 3). Interest-
ingly, the majority (70 %, n = 14/20) of patients with a
positive tumor base also had positive side surgical margins
(p-value 0.026, statistically significant) [Table 2, Fig. 3]
while most (84.2 %, n = 16/19) of our patients without
lymph node involvement had negative side surgical mar-
gins with only 15.8 % positive margins (p-value 0.000,
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highly statistically significant) [Table 3, Fig. 3]. This
implies that tumors which were not locally invasive were
also not likely to metastasize.
Furthermore, increased age at diagnosis appeared to
be associated with larger primary tumor size of T3 and
T4 (p-value 0.049). The association between the patient’s
age at diagnosis and histological grade of tumor was not
statistically significant.
Discussion
The clinical management of breast cancer patients at
MNH and Tumaini Hospital (source hospitals) involves
surgical treatment of patients followed by adjuvant
radiotherapy/chemotherapy at ORCI (destination hos-
pital). Patients are further followed up at ORCI clinics
and will only return to MNH in case of local recurrence
requiring surgical treatment or when they have compli-
cations of distant metastases such as pleural effusion re-
quiring underwater seal drainage. This protocol hinders
surgeons at source hospitals from following up these pa-
tients to understand how they fare after treatment at the
destination hospital. It thus becomes difficult to establish
the prognosis and survival of patients with breast cancer
treated at MNH as well as Tumaini Hospital.
In breast cancer some factors have been reported to
constitute risks to developing the disease; including
early age at menarche, late menopause, delay in first
live birth, family history as well as use of hormonal
contraceptives [19, 20].
In this study, 89.4 % of study population attained me-
narche after the age of 11 years, with mean age of
14.3 years which is the same as what was reported from
Tanzania previously [8]. Furthermore, young age at diag-
nosis has been associated with aggressive disease and
poor prognosis [21]. A retrospective study done in
Tanzania among females with breast cancer recorded in
the Cancer Registry between 1974 and 1987 suggested
that there was a younger age of onset among Tanzanians
and in those from other sub-Saharan African countries,
Latin America and Asia when compared with those from
North America/Northern Europe [2, 22–24]. Further-
more, the age at menarche as well as that at first child-
birth indicates a long reproductive career as influencing
the risk of breast cancer in our settings. The age range
of 28–79 years also suggests that we are seeing them at
younger ages. This is also supported by the mean age of
52 years in our study which is much lower than that of
64 years reported among African Americans previously
[25]. The mean age seems to be much lower in West Af-
rica as reported previously and all this suggests that
probably the biological behavior and pathogenesis of
breast cancer in Africa could be different from that in
Western industrialized countries [25, 26].
Regarding other socio-demographic factors influencing
breast cancer risk and prognosis, the finding that our co-
hort included a majority of postmenopausal differed
from that in Nigeria probably due to ethno-demographic
and geographic as well as other factors [27]. Importantly,
menopause status is an indicator of prognosis where
premenopausal women appear to have a more unfavour-
able prognosis than their postmenopausal counterparts
[22, 28]. Furthermore, our results agree with Nigerian
and other studies on parity and alcohol consumption as
being associated with breast cancer [29–31]. Likewise,
our finding of a significant number of hormonal contra-
ceptives users among our cohort agrees with previous
reports [32]. Conversely, cigarette smoking did not seem
to be an important characteristic among our breast can-
cer patients as the case could be elsewhere [25, 31].
Our current finding of a positive family history of
breast cancer of 14 % in our cohort appears to be much
higher than those reported from Nigeria [26, 33] and
generally indicates that it is an important risk and prog-
nostic factor in our settings. A Cypriot study found that
family history is the strongest predictor of breast cancr
risk in their population [19]. Furthermore, in the present
Table 1 Prognostic indicators for breast carcinoma in the study
population
Prognostic indicator Number of patients No.(%)
Clinical Stage
Stage I 0 (0)
Stage II 14 (16.3)
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study, the size of primary tumor appeared to increase
with increasing age at diagnosis while patients with node
positive disease were diagnosed at an earlier age than
those who were negative. The variation of age with
tumor size is expected as it takes a while for tumors to
grow while lymphnode involvement at an earlier age im-
plies increased aggressiveness. Thus, the larger primary
tumor size and frequent tumor infiltration of the skin in
our current study representing a high (T4) stage is re-
flective of advanced disease at diagnosis. This is most
likely due delayed hospital presentation in part due to
the behaviour of breast cancer which is painless initially,
ignorance, seeing traditional healers before consulting
modern medical care and a poorly organized referral
system.. This frequent T4 stage at diagnosis is well in
agreement with a previous Tanzanian report showing
the mean tumor size to be 8 cm and none of them was
less than 2 cm. Moreover, 68.8 % of the tumors in the
same study exceeded 5 cm in their greatest diameter [8].
These findings are in contrast to a previous report from
Cuba where T1 and T2 disease were more frequent (49.2
and 45.7 %) respectively [34]. The difference could be
due to better existing screening programs in Cuba
resulting in diagnosis at an earlier stage with smaller pri-
mary tumors size. It is noteworthy that tumor size has
been found to be the strongest predictive factor for re-
lapse even in node negative patients [35]. Thus, the find-
ings of our study regarding primary tumor size indicate
increased likelihood patients relapsing and therefore less
favourable prognosis.
In the current study, the majority of patients had
tumor positive axillary nodes. Axillary lymph node
status is the most important prognostic factor in
breast carcinoma and prognosis worsens with increas-
ing number of metastatic lymph nodes [36]. Accord-
ing to the American Joint Committee on Cancer
(AJCC)/International Union against Cancer (UICC)
tumor (T)-node (N)-metastasis (M) classification,
nodal disease is classified in three groups based on
the number of axillary metastatic lymph nodes: N1,
1–3 metastatic lymph node(s), N2, 4–9 metastatic
lymph nodes and N3, 10 or more metastatic lymph
nodes [37]. In our index study, 42.7 % of patients had
N2 disease which is an unfavourable prognostic indi-
cator. Our findings are in contrast with those re-




Fig. 1 a: Histological section showing a well-differentiated ductal carcinoma of the breast (x 100). b Histological section showing a well-differentiated
ductal carcinoma of the breast (x 400). c Histological section showing a moderately-differentiated ductal carcinoma of the breast (x 100). d Histological
section showing a moderately-differentiated ductal carcinoma of the breast (x 400). e Histological section showing a poorly-differentiated ductal carcinoma
of the breast (x 100). f Histological section showing a poorly-differentiated ductal carcinoma of the breast (x 400)
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tumors examined were node-negative (N0), 25.7 % had N1
disease, and 27.4 % had N2 disease [34]. The differences
could in part be due to better screening programmes in
Cuba thus breast cancer is diagnosed early before develop-
ing metastases. Since studies have shown increased tumor
recurrence among patients with metastatic axillary nodes of
up to 70 % within 10 years after mastectomy [38]. Most of
patients treated at MNH and Tumaini Hospital for breast
cancer are likely to have poor prognosis due to high num-
ber of metastatic axillary nodes.
As expected, in the current study, most women had
invasive ductal carcinoma. This is quite in concordance
with many previous studies reporting similar histological
findings including a study in Japan which found invasive
ductal carcinoma in 90 % of patients with breast cancer,
5 % had invasive lobular carcinoma, 1.5 % medullary car-
cinoma and 3 % mucinous type [39]. In Nigeria, compar-
able findings were reported where most (95 %) patients
had infiltrating ductal carcinoma and 5 % were papillary,
lobular or unspecified types [33]. These findings of our
current study imply that most of patients in our studied
institutions have an increased risk to poor prognosis be-
cause of the dominant histological tumor type.
Furthermore, in our index study intermediate and high
histological grades were commoner than low grade tu-
mors and these findings are in line with what was re-
ported among Cuban women who underwent surgery
for breast cancer, whereby 54.87 % were intermediate
grade and 30.82 % were high grade tumors [34]. Simi-
larly, an Irish study involving 293 cases of invasive pri-
mary breast cancer, showed that 53 % of cases had low
and intermediate grades together, while 47 % had high
grade tumor, further implying that higher grades as be-
ing more frequent had intermediate been grouped with
high grade which by itself is almost half the proportion
[40]. As expected, higher grades have been quite consist-
ently associated with lower long-term survival as well as
with increasing tumor size [28, 41]. On the other hand,
there was no association between mean age at diagnosis
with the histological grade of tumor. The higher histo-
logical grades seen in the index study are proportional




Fig. 2 a Histological section showing a pleomorphic carcinoma of the breast (x 100). b Histological section showing a pleomorphic carcinoma of
the breast (x 400). c Histological section showing a cutaneous involvement (Ulceration) by carcinoma of the breast making it stage T4 (x 100).
d Histological section showing a cutaneous involvement (Ulceration) by carcinoma of the breast making it stage T4 (x 400). e Histological section
showing a lymphnode involvement by carcinoma of the breast (x 100). f Histological section showing a lymphnode involvement by carcinoma of
the breast (x 400)
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which is usually associated with higher histological
grades. This implies that about 73 % of patients under-
going MRM at our institutions are likely to have a re-
lapse due to the histological grades of their tumors.
Clinical stage of the disease at time of diagnosis can sig-
nificantly affect the prognosis and outcome of the patient.
Most (83.5 %) of patients in the present study had stage
three disease, 16.5 % stage two and none had stage one.
Ten years ago, a pathological study of surgical specimens of
patients with breast cancer was done at MNH; 5.2 % were
stage II and 57 % stage III, none were stage I disease [8]. In
Ibadan Nigeria, a study involving 763 cases of breast cancer
showed 2 % had stage I disease, 13 % stage II and 46 %
stage III [38]. Conversely, in Canada most patients are seen
at early stage of disease, thus in one study 37 % had stage I
disease, 38.5 % stage II and 7.1 % stage III disease [42].
Among Cuban women, breast cancer was as well diagnosed
at early stage compared to Tanzanian, 23 % stage I, 59.94 %
stage II and 15.3 % stage III disease [34]. Clinical stage II
and III disease are considered high risk stage for relapse as
well as overall survival. The late presentation seen in our
study population may be due to lack of well established and
comprehensive screening programs as well as myths on
breast cancer surgery and adjuvant therapy which are
linked to death.
A tumor positive surgical margin is definitely a risk
factor for local recurrence in breast cancer. In our
present study, 25 % of patients had positive surgical
margins of which 70 % had both base and side margins
positive for tumor. Considering that a large number of
patients in our cohort presented with a locally advanced
disease, it was not expected that the frequency of posi-
tive surgical margins would be so low and the reasons
for this discrepancy are not yet clear. Adjuvant local
radiotherapy and systemic therapy may limit tumor re-
currence but not to levels observed in patients with
negative margins [43–45].
Conclusions
This study has found that at the time of diagnosis, most
of our patients appear to have unfavourable prognostic
factors leading to decreased survival including locally ad-
vanced tumors, a younger presenting age, frequent
intermediate-to-high tumor grades as well as larger pri-
mary tumor sizes. Majority of our patients were post-
menopausal which seemd to be the only indicator of
favourable prognosis in our index study. Furthermore,
risk factors including long reproductive career, multipar-
ity, use of hormonal contraceptives, alcohol consump-
tion and a positive family history appeared to be
relatively frequent among breast cancer patients in our
cohort although larger samples and randomized studies
are needed to ascertain this.
However, following mastectomy the percentage of posi-
tive margins is low thus less likelihood of local recurrence
when margin status alone is taken into consideration.
Thus, the majority of our patients may not require local
radiotherapy after mastectomy. We recommend sustain-
able and comprehensive screening programs, at least by
increased awareness and self-examination in our settings.
Further tests including mammography, breast ultra-sound
scan and fine-needle aspiration cytology which are more
expensive can be reserved for those found to have suspi-
cious lumps. Early definitive diagnosis as well as timely
and good surgical intervention will also improve breast
cancer outcome in Tanzania.




Lymph node status No. (%)
Positive Negative Total
Yes 17 (27.9 %) 3 (15.8 %) 20 (25 %)
No 44 (72.1 %) 16 (84.2 %) 60 (75 %)
Total 61 (100 %) 19 (100 %) 80 (100 %)
Most of our patients with lymph node negative disease had negative surgical
margins (side) (84.2 %) with only 15.8 % positive margins (P-value 0.000,
highly statistically significant)
Fig. 3 A bar chart showing the percentage tumor positivity in
surgical margins among post-MRM female breast cancer patients at
MNH and Tumaini Hospital
Table 2 The association between the side surgical margins and
the base of the tumor
Side surgical margins positive for tumor Base positive for tumor
Yes (%) No (%) Total (%)
Yes 14 (70) 6 (10) 20 (25)
No 6 (30) 54 (90) 60 (75)
Total 20 (100) 60 (100) 80 (100)
Seventy percent (70 %) of patients with positive tumor base had positive side
surgical margins (P-value 0.026, statistically significant)
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